Combination Treatment for Operable Stage III Skin Melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether combining a new drug called PRTX007-003 with pembrolizumab (an immunotherapy) can help prevent melanoma from returning after surgery. You would receive both treatments after your tumor is surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Stage III melanoma (cancer that has spread to nearby lymph nodes) that can be surgically removed
- Your melanoma is cutaneous (starts in the skin), not uveal or mucosal melanoma
- You have not received any previous systemic cancer treatments (chemotherapy, immunotherapy, or targeted therapy) for melanoma
- You are in good enough health to tolerate treatment (ECOG performance status 0–2, meaning you can do most daily activities)
- You have adequate organ function (healthy kidneys, liver, and blood counts)
- You do not have an active autoimmune disease being treated with systemic medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.